-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Stoke Therapeutics, Raises Price Target to $36

Benzinga·01/05/2026 12:10:36
語音播報
Canaccord Genuity analyst Sumant Kulkarni maintains Stoke Therapeutics (NASDAQ:STOK) with a Buy and raises the price target from $28 to $36.